Having rejected a bid by Medtronic, Cyberonics believes its epilepsy business is the basis for much bigger opportunities. Cyberonics holds key method patents on a device for vagus nerve stimulation, which it refers to as an "implantable pacemaker for the brain." It believes the technology has far-reaching clinical applications for neurological disorders traditionally treated by drugs. A body of literature demonstrates the product's efficacy and ease of use in selected epilepsy patients. The product has been FDA approved and on the market since 1997. However, Cyberonics has yet to prove its device will work in broader applications like depression, which have larger markets but also significant competition from drugs.
By Wendy Diller
The intimate Waldorf-Astoria dining room was humming with well-dressed people, luscious flower displays, lavish spreads of food and wine—a set...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
